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Abstract
Background: The tumor suppressor gene CDH1 is critical for intercellular adhesion. In our previous work, we
reported a nonfunctional CDH1 transcript that lacks the final 83 base pairs of exon 8 (1054del83). In this work,
we probed the role of histone epigenetic modifications as well as DNA methylation in selection of this isoform.
Methods: RT-qPCR was used to detect CDH1 RNA expression. Methylation of CDH1 was analyzed by bisulphite
sequencing PCR. ChIP assay was performed to show histones level. Cell lines were treated with DNA methyltransferase
inhibitor AZA, HDAC inhibitor TSA, or siRNA oligonucleotides to test regulation of CDH1 splicing.
Results: Greater CDH1 1054del83 transcripts were observed in gastric cancer (GC) cell lines than human gastric
mucosal epithelial cell line GES-1. All the cell lines showed significant methylation pattern at the CpG sites of CDH1
exon 8. AZA treatment did not influence selection of 1054del83 transcripts. A significant decrease in acetylation for
histones H3 and H4K16Ac in an internal region of the CDH1 gene surrounding the alternative exon 8 were detected
in GC cell lines. Treatment with TSA preferentially expressed the correctly spliced transcript and not the exon 8
skipped aberrant transcripts, showing that histone acetylation was involved in the splicing regulation. SiRNA-mediated
knockdown of SETD2 (The specific methyltransferase of H3K36) decreased exclusion of exon 8, suggesting that the
presence of this mark correlates with increased skipping of the final 83 base pairs of CDH1 exon 8. However, CDH1
splicing was not affected by SRSF2 knockdown.
Conclusions: H3K36me3 correlates with increased skipping of the final 83 base pairs of CDH1 exon 8. Histone
acetylation was involved in the splicing regulation as well.
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Background
Gastric cancer (GC) is one of the most common malig-
nancies worldwide, with the highest incidence rates in
Eastern Asia [1]. It is believed that GC is a multistep
process during which some genetic alterations such as
oncogene activation, tumor suppressor gene inactivation
and DNA repair deficiency are responsible for the over-
all outcome of the cancer.
The tumor suppressor gene CDH1 (E-cadherin) is crit-
ical for intercellular adhesion [2, 3]. CDH1 gene mutations
occurred frequently in hereditary diffuse gastric cancer
(HDGC) [4, 5]. In our previous work in GC patients, we
identified several germline mutations in CDH1 gene [6, 7].
Most human genes are alternatively spliced in a cell
type–and tissue-specific manner, and abnormalities of
pre-mRNA alternative splicing contribute to disease. In
our previous work, we reported an alternatively spliced,
nonfunctional CDH1 transcript that lacks the final 83
base pairs of exon 8 (1054del83) of the gene. This non-
functional transcript has a premature termination codon
(PTC) with 358 aminos and is degraded by the nonsense
mediated decay (NMD) pathway. We demonstrated this
transcript is a frequent event in Chinese GC patients [7].
Analysis of alternative splicing regulation has trad-
itionally focused on RNA sequence elements and their
associated splicing factors [8–11]. But 1054del83 tran-
script seemed to be not triggered by RNA sequence
* Correspondence: ymfan@nju.edu.cn
Department of Medical Genetics, Jiangsu Key Laboratory of Molecular
Medicine, Medical School, Nanjing University, Hankou Road 22, Nanjing
210093, China
© 2015 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. BMC Cancer  (2015) 15:954 
DOI 10.1186/s12885-015-1983-5
elements [7]. Research disclosed that pre-mRNA splicing
generally proceeds cotranscriptionally [12], and thus give
the basis of epigenetic regulation of alternative splicing.
Recent studies provided evidence that alternative splice
site choice is influenced by chromatin structure and his-
tone modifications mainly through two mechanisms, kin-
etic coupling [13–18] or chromatin-splicing adaptor
systems [13, 19–22]. Given these observations, we probed
the role of histone epigenetic modifications as well as




The GC cell lines SGC-7901, BGC-823 and MGC80-3
(Purchased from Shanghai Cell Bank of Chinese Acad-
emy of Sciences, China) and human gastric mucosal
epithelial cell line GES-1 (Purchased from Cell bank of
Xiangya Medical School, Central South University,
China) were cultured in DMEM medium, supplemented
with 10 % fetal calf serum, at 37 °C with 5 % CO2. Emet-
ine treatment was done at concentration of 100 μg/ml
for 8 h before harvest of the cells. The three GC cell
lines were poorly differentiated adenocarcinoma cells.
No ethics approval was required for this study.
RNA extraction and quantitative reverse transcription
polymerase chain reaction (RT-qPCR)
Total RNA from GC cell lines or human gastric mucosal
epithelial cell line was extracted using RNAiso Plus
(TaKaRa Biotechnology (Dalian) Co., Ltd.). RT–qPCR
was performed in two steps. First strand cDNA synthesis
was performed using PrimerScript RT reagent Kit (TaKaRa)
with random DNA hexamers and oligo-dT primer accord-
ing to the manufacturer’s protocol. CDH1 expression is
analyzed by a TaqMan qPCR experiment on ABI StepOne
Plus Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). The qPCR reaction condition and se-
quences of PCR primers and TaqMan probes are as previ-
ous reported [7].
DNA methylation assay
DNA was treated with bisulfite using the CpGenome™
DNA Modification Kit (CHEMICON International, Te-
mecula, CA, USA) according to manufacturer’s proto-
col. Methylation status of CpG sites of CDH1 exon
7–9 was analyzed by bisulphite sequencing PCR (BSP)
on an ABI 3130-Avant automated sequencer (Applied









Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed by using the EZ-Magna
ChIP Kit (catalog no.17-408; Millipore, USA) according
to the manufacturer’s instructions. Briefly, 1 × 106 cells
were fixed with 1 % formaldehyde for 10 min at 37 °C.
The cells were washed extensively with PBS, and the
chromatin was sheared by sonication (Bioruptor sonicator)
to 200–500 bp fragments. The cross-linked histone-DNA
complex was immunoprecipitated with anti-H3K36me3,
anti-H3K4me2, anti-H4K16ac, or anti-pan acetylated-H3
(anti-acH3) antibodies (Millipore). Normal rabbit IgG was
used as negative controls. DNA was obtained from the
crosslinked complex and equal amounts of input and
immunoprecipitated DNA 1.0 ng were used to perform
SYBR Green real-time PCR on ABI StepOne Plus Real-
Time PCR System (Applied Biosystems). The qPCR reac-
tion mixture contained DNA, the forward primer, reverse
primer, ROX Reference Dye, SYBR and Premix Ex Taq™
(TaKaRa). Primers are described in Additional file 1: Table
S1. The thermal cycle conditions for assay were as follows:
95 °C at 30 sec, 40 cycles at 95 °C for 15 sec and 60 °C for
30 sec.
CDH1 expression with DNA methyltransferase inhibitor
AZA or histone deacetylases (HDAC) inhibitor trichostatin
A (TSA)
To test whether CDH1 splicing is affected by DNA
methylation or histone acetylation status, the GC cell
lines SGC-7901, BGC-823 and MGC80-3 and human
gastric mucosal epithelial cell line GES-1 were treated
with DNA methyltransferase inhibitor AZA or HDAC
inhibitor TSA. 5-aza-2′deoxycytidine (Sigma-Aldrich)
was added to the medium to be 1 μM. Treatments were
maintained for 72 h. TSA (Sigma-Aldrich) was added
to culture to be 0.5 μM 12 h before the end of the ex-
periment. CDH1 RNA expression was determined by
RT-qPCR analysis.
siRNA-mediated transient knockdown
Downregulation of SETD2 or SRSF2 was performed
using siRNA oligonucleotides (Guangzhou Ribobio Co.,
LTD, China). SiRNA oligos against human SETD2 or
SRSF2 were delivered to cells at 50 nM following the man-
ufacturer’s instructions. Normal negative control was used
as control. Forty eight hours after transfections, cells were
harvested and the knockdown efficiencies were analyzed
by RT-qPCR and changes in CDH1 splicing were analyzed
as mentioned above.
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Comparative in silico analysis
NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html)
were used to predict splice acceptors and donors around
CDH1 exon 8. We used the ESEfinder program (http://
rulai.cshl.edu/tools/ESE) to identify exonic splicing en-
hancers (ESEs) [23].
Statistical analysis
Differences in transcripts level between groups were an-
alyzed by ANOVA (analysis of variance) and SNK-q test.
All P values are two-sided; P < 0.05 was considered sta-
tistically significant.
Result
Two alternative donor sites were in CDH1 exon 8 and
flanking sequences
We find two donor sites in CDH1 exon 8 and flanking
sequences which will produce the 1054del83 transcript
and normal transcript, respectively [7] (Fig. 1). ESEfinder
predicted that there are two extra SRSF2 motifs flanking
donor site 1 (Fig. 1a).
GC cells carry significant more CDH1 1054del83 isoform
than GES-1 cells
RT-qPCR revealed the coexistence of the normal CDH1
transcript and CDH1 1054del83 transcript in the GC cell
lines SGC-7901, BGC-823 and MGC80-3 and human gas-
tric mucosal epithelial cell line GES-1. A lower expression
of the normal CDH1 and a higher level of CDH1
1054del83 transcript are detected in GC cell lines SGC-
7901 and BGC-823 compared to GES-1 (Fig. 2a and b).
Taken together, there is a higher ratio of CDH1 1054del83
vs CDH1 normal transcript in GC cell lines SGC-7901
and BGC-823 than in GES-1 (Fig. 2c). However, in GC cell
line MGC80-3, though a lower expression of the normal
CDH1 was detected (Fig. 2a), no difference existed for
level of CDH1 1054del83 transcript between MGC80-3
and GES-1 (Fig. 2b and c). So, in most of the experiments
carried out behind, we used GC cell lines SGC-7901 and
BGC-823 for comparing splicing with GES-1.
Hypermethylation was shown at the CpG sites of CDH1
exon 8 and the nearby exons
All the three GC cell lines SGC-7901, BGC-823 and
MGC80-3, and the human gastric mucosal epithelial
cell line GES-1 showed significant methylation pattern
at the CpG sites of CDH1 exon 8 and the nearby exons
(Fig. 3, Additional file 2: Figure S1 and Additional file
3: Figure S2).
Lower level of histone acetylation and higher level of
H3K36 tri-methylation were detected around CDH1 exon
8 regions in GC cell lines compared to GES-1
To get a picture of the distribution of histone modifi-
cations across the CDH1 gene, we performed ChIP
assay. We first performed ChIP of H3 acetylation and
H4K16Ac in extracts from cells. ChIP results showed a
significant decrease in acetylation for histones H3 in
an internal region of the CDH1 gene surrounding the
alternative exon 8 in SGC-7901 cells compared to hu-
man gastric mucosal epithelial cell line GES-1. A lower
H4K16Ac were detected in this region both in SGC-
7901 and BGC-823 cells compared to GES-1 (Fig. 4).
To investigate if CDH1 exon 8 splicing could be
modulated by a change in the histone methylation pat-
terns, we performed ChIP studies using antibodies
recognizing methylation at different lysines of histone
H3. No regular difference of H3K4Me2 was detected
between GC cell lines and human gastric mucosal epi-
thelial cell line GES-1 (Fig. 4). To the contrary, ana-
lysis of H3K36 tri-methylation revealed higher level of
H3K36 tri-methylation around the CDH1 exon 8 re-
gions in SGC-7901 and BGC-823 compared to GES-1
(Fig. 4).
Fig. 1 a Splice sites prediction by bioinformatic analysis. Capital letters show CDH1 exon 8 and lowercases, the flanking intron sequences. The
italic characters indicate SRSF2 motifs flanking donor site 1. b Schematic diagram of alternative splicing of CDH1 exon 8
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TSA treatment of cells led to a significant change in
splicing in favor of CDH1 normal transcript, while AZA
treatment did not affect the amount of CDH1 full length
and CDH1 1054del83 splice isoform
To explore a putative regulation of the alternative splicing
of CDH1 exon 8 by means of histone acetylation or DNA
methylation, we treated the GC cell lines SGC-7901,
BGC-823, and MGC80-3 and human gastric mucosal epi-
thelial cell line GES-1 with HDAC inhibitor TSA or DNA
methyltransferase inhibitor AZA. As shown in Fig. 5,
AZA treatment did not influence ratios of CDH1
1054del83 transcript vs CDH1 normal transcript in all
the four cell lines. TSA deceased ratios of CDH1
1054del83 transcript vs CDH1 normal transcript in the
two GC cell lines SGC-7901 and BGC-823. Detail analysis
showed after TSA treatment, CDH1 normal transcript
incerased to about 2 fold, while the CDH1 1054del83
transcript did not change significantly (Fig. 6).
siSETD treatment showed a shift in the splicing of the
CDH1 pre-mRNAs in favor of CDH1 normal transcript
A value of nearly 90 % SETD2 knockdown was deter-
mined by qPCR analysis after siSETD2-003 treatment of
GC cell lines and human gastric mucosal epithelial cell
line (Fig. 7a and Additional file 4: Figure S3). Decreased
ratios of CDH1 1054del83 transcript vs CDH1 normal
transcript was observed in all the three cell lines transi-
ently transfected with SETD2 siRNA compared to cells
transfected with scramble (nontargeting) siRNA (Fig. 7b).
Knockdown of SRSF2 did not influence ratios of CDH1
alternative transcripts
The interference efficiency of the three kinds of siSRSF2
can all get about 90 % for SRSF2 expression (Fig. 8a and
Additional file 5: Figure S4). SiSRSF2 treatment did not
influence ratios of CDH1 1054del83 transcript vs CDH1
normal transcript in all the three kinds of cells (Fig. 8b).
Fig. 2 Expression of CDH1 normal transcript (a), CDH1 1054del83 transcript (b), and ratio of expression value of CDH1 1054del83 transcript vs CDH1
normal transcript (c) in human gastric mucosal epithelial cell line GES-1 and the GC cell lines SGC-7901, BGC-823 and MGC80-3. The expression level in
GES-1 was set to 1. The star * means P < 0.05, indicating statistically significant
Fig. 3 Methylation status of CDH1 exon 8 in human gastric mucosal epithelial cell line GES-1 (a) and the GC cell lines SGC-7901 (b), BGC-823
(c) and MGC80-3 (d). DNA isolated from cells shows a high C content at all CpGs attributable to reduced bisulfite modification because of complete
methylation of the DNA
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Discussion
The CDH1 gene, a calcium-dependent transmembrane
glycoprotein, is critical for epithelial architecture and
intercellular adhesion. Sharma et al. have demonstrated
the existence of transcripts with CDH1 exon 11 skip-
ping in chronic lymphocytic leukemia cells and head
and neck cancer cells [24, 25]. Further analysis showed
a low histone acetylating level of CDH1 exon 11 in
chronic lymphocytic leukemia cells. HDAC inhibitors
MS-275 treatment increased the level of normal CDH1
transcript [26].
The 1054del83 transcript had been reported in HDGC
[27]. Our previous study demonstrated this aberrant
transcript existed in GC patients harboring no muta-
tions, which suggested it could be a frequent event in
GC patients [7]. In this study, we further show the skip-
ping is not a specific feature of GC, since these tran-
scripts occurred in GC cell lines and the human gastric
mucosal epithelial cell line GES-1 as well. However, GC
cells carry significant more CDH1 1054del83 isoform
than GES-1 cells (Fig. 2).
The CDH1 1054del83 isoform was suggested to move
the reading frame and create a PTC with 358 aminos,
which would presumably lead to nonsense mediated
mRNA decay. CDH1 1054del83 will serve to down-
regulate the amount of full-length CDH1 mRNA/protein
Fig. 4 Histone modification patterns of CDH1 in SGC-7901 (a) and BGC-823 (b) compared to GES-1. The graphs demonstrate fold differences of
distinct histone modifications at different region of CDH1 between SGC-7901 or BGC-823 and GES-1 cells
Fig. 5 The relative folds of ratios of CDH1 1054del83 transcript vs CDH1 normal transcript after AZA or TSA treatment. The values were calculated as
(2-ΔCt (1054del83 transcript-actin)/2-ΔCt (normal transcript-actin)). Relative folds of ratios of untreated cell lines serve as 1. The star * means P < 0.05, indicating
statistically significant
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produced and lead to reduction of CDH1 activity. We
might suggest the increase of CDH1 1054del83 isoform
might lead to GC.
There might be a natural balance of the two alternative
splice products (normal CDH1 and 1054del83 transcripts).
To explore a putative regulation of the alternative splicing
of CDH1 exon 8 by means of epigenetic, we carried out in
vitro experiment.
Shukla S has reported DNA methylation could regu-
late alternative splicing in CD45 exon5 [18]. In our data,
there is no correlation between DNA methylation and
CDH1 exon 8 alternative splicing (Fig. 5). The influence
of DNA methylation modifications on exon skipping
might be critical in some genes but not in others.
In the period of transcription, transcriptional elongation
speed is modulated by the dynamic balance of acetylation
and deacetylation of histones. Recent researches have indi-
cated that local histone acetylation patterns influence
splice site selection [14–17].
In our study, a significant decrease in acetylation for
histones H3 and H4K16Ac in an internal region of the
CDH1 gene surrounding the alternative exon 8 were
detected in GC cell lines. Treatment with TSA prefer-
entially expressed the correctly spliced transcript and
not the exon 8 skipped aberrant transcripts. A derived
hypothesis would be that low level of histone acetyl-
ation in GC cells would cause a more compact chroma-
tin structure, thus slower transcriptional elongation
speed of Pol II and more time for suboptimal splicing
signal (donor site 1) to be recognized by the splicing
machinery, and thus the CDH1 1054del83 transcript is
enhanced. Inhibition of HDAC activity with TSA will
increase acetylation of H3 and H4 and induce chroma-
tin opening and faster rate of transcriptional elong-
ation, decreasing the use of donor site 1 and thus less
the 1054del83 transcript.
Analysis of histone methylation revealed an increase
for H3K36 tri-methylation surrounding the CDH1 exon
8 regions in GC cell lines SGC-7901 and BGC-823 com-
pared to human gastric mucosal epithelial cell line GES-
1 (Fig. 4). Down-regulation of the H3-K36 methyltrans-
ferase SETD2 by RNA interference showed a shift in the
splicing of the CDH1 pre-mRNAs in favor of CDH1 nor-
mal transcript (Fig. 7). These results demonstrate that
histone modifications H3K36 tri-methylation can en-
hance the use of donor site 1. The presence of this mark
correlates with increased exclusion of the final 83 base
pairs of CDH1 exon 8 in the mature CDH1 mRNA. Our
Fig. 6 The level change of CDH1 normal transcript and CDH1 1054del83 transcript after TSA treatment in SGC-7901 (a) and BGC-823 (b). The values
were calculated as 2-ΔCt (1054del83 transcript-actin) or 2-ΔCt (normal transcript-actin). The values of untreated cell lines were set to 1. The star * means
P < 0.05, indicating statistically significant
Fig. 7 CDH1 expression after siSETD2 treatment. a Interference efficiency of the three kinds of siSETD2 in GES-1 cells. The values were calculated
as 2-ΔCt (SETD2-actin). The star * means P < 0.05, indicating statistically significant. b The relative folds of ratios of CDH1 1054del83 transcript vs CDH1
normal transcript after siSETD2-003 treatment. The values were calculated as (2-ΔCt (1054del83 transcript-actin)/2-ΔCt (normal transcript-actin)). Relative folds of
ratios of untreated cell lines serve as 1
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results demonstrate a role for H3K36 tri-methylation in
alternative splicing control. But how does it work? Phys-
ical interaction between several chromatin-associated
proteins and splicing components has been reported,
which have been elucidated as chromatin-splicing
adaptor systems [13, 19–22]. ESEfinder predicted that
compared to donor site 2 of CDH1 exon 8, there are
two extra ESE motifs flanking donor site 1 region which
can be bind by SRSF2, a sequence-specific RNA binding
factor that promotes spliceosome formation (Fig. 1). We
propose that the H3K36me3 mark might be recognized
by chromatin remodeling proteins, which directly recruits
splicing factors SRSF2 to the exonic splicing enhancer
element surrounding donor site 1 of CDH1 exon 8 to in-
crease 1054del83 transcript. However, knockdown of
SRSF2 did not influence ratios of CDH1 1054del83 tran-
script vs CDH1 normal transcript in the GC cell lines and
GES-1 cell line (Fig. 8). Thus, we could not get a proof for
the effect of SRSF2 on splicing of CDH1 pre-mRNA.
These results indicate that H3K36 tri-methylation play a
role in CDH1 splice site selection, but the recruitment of
chromatin remodeling proteins and splicing factors is
more complicated than predicted. Additional studies are
needed to disclose the mechanism how this happens.
Though GC cell lines SGC-7901 and BGC-823 carry
significant more CDH1 1054del83 isoform than GES-1
cell line, the difference did not exist between GC cell
lines MGC80-3 and GES-1 (Fig. 2). The HDAC inhibi-
tor TSA led to a significant change in splicing in favor
of CDH1 normal transcript both in the two GC cell
lines SGC-7901 and BGC-823, but not in GC cell line
MGC80-3 (Fig. 5). The influence of epigenetic modifi-
cations on exon skipping might be critical in some cells
but not in others.
Conclusions
The chromosomal region encompassing the CDH1 exon
8 is highly enriched in H3K36me3 marks in GC cells
compared to human gastric mucosal epithelial cells, and
the presence of this mark correlates with increased skip-
ping of the final 83 base pairs of CDH1 exon 8 in the
mature CDH1 mRNA. We propose that the epigenetic
modification patterns, such as histone acetylation might
have a role in CDH1 exon 8 alternative splicing regula-
tions as well. The linking between histone modifica-
tions and splicing regulation might be important in GC
occurrence.
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Additional file 2: Figure S1. Methylation status of CDH1 exon 7 in
human gastric mucosal epithelial cell line GES-1 and the GC cell lines
SGC-7901, BGC-823 and MGC80-3. DNA isolated from cells shows a high C
content at all CpGs attributable to reduced bisulfite modification because of
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Additional file 3: Figure S2. Methylation status of CDH1 exon 9 in
human gastric mucosal epithelial cell line GES-1 and the GC cell lines
SGC-7901, BGC-823 and MGC80-3. DNA isolated from cells shows a high
C content at all CpGs attributable to reduced bisulfite modification
because of nearly complete methylation of the DNA. (TIF 1354 kb)
Additional file 4: Figure S3. Interference efficiency of the three kinds
of siSETD2 in SGC-7901 (A) and BGC-823 (B) cells. The values were calculated
as 2-ΔCt (SETD2-actin). The star * means P < 0.05, indicating statistically
significant. (TIF 147 kb)
Additional file 5: Figure S4. Interference efficiency of the three kinds
of siSRSF2 in SGC-7901 (A) and BGC-823 (B) cells. The values were calculated
as 2-ΔCt (SRSF2-actin). The star * means P < 0.05, indicating statistically
significant. (TIF 147 kb)
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